In the latest close session, Eli Lilly (LLY) was down 1.16% at $799.57. Meanwhile, the Dow gained 0.47%, and the Nasdaq, a tech-heavy index, lost 0.16%. The stock of drugmaker has risen by 7.15% in ...

Eli Lilly (LLY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

Eli Lilly (LLY) reached $855.35 at the closing of the latest trading day, reflecting a +1.14% change compared to its last close.

Florida-based wealth advisory J. L. Bainbridge disclosed a purchase of Eli Lilly and Company valued at approximately $45.6 ...

Eli Lilly stock has recovered resoundingly, outperforming the S&P 500, Novo Nordisk, and healthcare peers after a period of ...

Pharmaceutical stocks gained Wednesday afternoon amid anticipation Pfizer's deal with the Trump administration could lead to ...

These two stocks have lagged the S&P 500 over the past year. Coca-Cola has raised its dividend for 63 straight years. Eli Lilly appeals to growth and income investors. These two underperforming stocks ...

Just one of the so-called Magnificent Seven megacap tech companies is expected to be a top 5 contributor to the S&P 500’s ...

Fundamentally, Eli Lilly represents a juggernaut in medical innovations. Recently, the company has taken a leadership role in ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. Berenberg analyst Kerry Holford downgraded Eli Lilly ...

Key Points Chesapeake sold 9,875 Eli Lilly and Company shares; estimated trade value of approximately $7.68 million, based on the average price for Q2 2025 Transaction represented 6.9% of fund AUM.

The Dow, S&P 500 and Nasdaq all rose this week, as investors shook off concerns about bad loans as well as trade tensions ...